Exact Sciences Corporation (EXAS)

NASDAQ: EXAS · Real-Time Price · USD
52.82
-0.61 (-1.14%)
Sep 16, 2025, 4:00 PM EDT - Market closed
-1.14%
Market Cap10.00B
Revenue (ttm)2.94B
Net Income (ttm)-1.01B
Shares Out 189.32M
EPS (ttm)-5.40
PE Ration/a
Forward PE74.19
Dividendn/a
Ex-Dividend Daten/a
Volume2,082,624
Open53.52
Previous Close53.43
Day's Range52.63 - 53.78
52-Week Range38.81 - 72.83
Beta1.05
AnalystsStrong Buy
Price Target67.38 (+27.57%)
Earnings DateNov 4, 2025

About EXAS

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Ri... [Read more]

Sector Healthcare
Founded 1995
Employees 7,000
Stock Exchange NASDAQ
Ticker Symbol EXAS
Full Company Profile

Financial Performance

In 2024, Exact Sciences's revenue was $2.76 billion, an increase of 10.37% compared to the previous year's $2.50 billion. Losses were -$1.03 billion, 404.0% more than in 2023.

Financial Statements

Analyst Summary

According to 22 analysts, the average rating for EXAS stock is "Strong Buy." The 12-month stock price target is $67.38, which is an increase of 27.57% from the latest price.

Price Target
$67.38
(27.57% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Exact Sciences CEO on Launch of Multi-Cancer Blood Test

Exact Sciences CEO and Chair Kevin Conroy discusses the company's new multi-cancer blood test and competitive environment. Speaking on "Bloomberg Open Interest," Conroy also comments on President Dona...

1 day ago - Bloomberg Markets and Finance

Exact Sciences Launches Cancerguard™, First-of-Its-Kind Multi-Cancer Early Detection Blood Test

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, today announced the launch of the Cancerguard™ test, a new multi-cancer early detection (MCED) bloo...

6 days ago - Business Wire

Exact Sciences Corporation (EXAS) Presents At Baird 2025 Global Healthcare Conference (Transcript)

Exact Sciences Corporation (NASDAQ:EXAS) Baird 2025 Global Healthcare Conference September 9, 2025 10:50 AM EDT Company Participants Kevin Conroy - Chairman of The Board & CEO Aaron Bloomer - Chief F...

6 days ago - Seeking Alpha

Exact Sciences Corporation (EXAS) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Exact Sciences Corporation (NASDAQ:EXAS) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 1:30 PM EDT Company Participants Aaron Bloomer - Chief Financial Officer Conference Call ...

12 days ago - Seeking Alpha

Legal Win for Geneoscopy as Exact Sciences Withdraws Preliminary Injunction Against ColoSense®

ST. LOUIS--(BUSINESS WIRE)--Geneoscopy announced that Exact Sciences has withdrawn its motion for a preliminary injunction regarding the '781 patent and the ‘746 patent.

25 days ago - Business Wire

Exact Sciences to Participate in September Investor Conferences

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the follow...

4 weeks ago - Business Wire

Top 3 Health Care Stocks That Are Preparing To Pump This Month

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: OMTNDM
5 weeks ago - Benzinga

Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025

We added key positions in Masimo, Exact Sciences, Eli Lilly, Penumbra, and Edwards Lifesciences, each with strong growth drivers and market leadership. Our investment in Masimo is supported by divesti...

Other symbols: ACLXBSXEWGHISRGLLYMASI
5 weeks ago - Seeking Alpha

Exact Sciences Dip A Chance To Buy As Freenome Deal Fortifies Future: Analyst

Exact Sciences Corp. EXAS on Thursday reported a second-quarter 2025 EPS loss of 1 cent, up from a 9-cent loss a year ago, beating the analyst consensus loss estimate of 19 cents.

5 weeks ago - Benzinga

Exact Sciences Corporation (EXAS) Q2 2025 Earnings Call Transcript

Exact Sciences Corporation (NASDAQ:EXAS) Q2 2025 Earnings Conference Call August 6, 2025 5:00 PM ET Company Participants Aaron Bloomer - Chief Financial Officer Derek Leckow - Vice President of Inves...

5 weeks ago - Seeking Alpha

Exact Sciences Announces Second Quarter 2025 Results

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $811 million for...

5 weeks ago - Business Wire

Exact Sciences Announces Exclusive License with Freenome for Blood-Based Colorectal Cancer Screening Tests

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, and Freenome, a biotechnology company pioneering an early cancer detec...

5 weeks ago - Business Wire

Exact Sciences and Humana Expand Colorectal Cancer Screening Partnership with Cologuard Plus™ Test

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced an expanded partnership with Humana Inc. to enhance ac...

6 weeks ago - Business Wire

Exact Sciences Schedules Second Quarter 2025 Earnings Call

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2...

2 months ago - Business Wire

Geneoscopy Wins Patent Trial and Appeal Board Decision, Invalidating All 20 Claims of Exact Sciences' '781 Patent

ST. LOUIS, Mo.--(BUSINESS WIRE)--Geneoscopy wins PTAB ruling as all 20 claims of Exact Sciences' '781 patent are invalidated, paving the way for continued advancement of ColoSense.

2 months ago - Business Wire

Exact Sciences Announces Medicare Coverage for Oncodetect™ Molecular Residual Disease Test in Colorectal Cancer

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that its Oncodetect™ molecular residual disease (MRD) ...

2 months ago - Business Wire

Exact Sciences Announces Expanded Clinical Validation of the Oncodetect™ Test and Molecular Residual Disease Innovation Roadmap

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced new data to be presented from the Beta-CORRECT clinica...

3 months ago - Business Wire

Exact Sciences to Participate in June Investor Conference

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the follow...

4 months ago - Business Wire

Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present ten abstracts at the 2025 American Soc...

4 months ago - Business Wire

Exact Sciences Earns 2025 Great Place To Work® Certification™

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today that it has been certified as a 2025 Great Place To Work® fo...

4 months ago - Business Wire

Exact Sciences Q1 Earnings: Decent Quarter, But Growth Story Not Compelling

Exact Sciences Corporation posted solid Q1 2025 earnings with revenues up 11% year-on-year, driven by strong performance in screening and Precision Oncology segments. Despite the sequential revenue de...

4 months ago - Seeking Alpha

Cancer Diagnostic Firm Exact Sciences' CEO Says Strong Q1 Paves Way For 'Transformative' 2025, Lifts Annual Guidance

Exact Sciences Corp. EXAS on Thursday reported a first-quarter 2025 EPS loss of 21 cents, down from a 37-cent loss a year ago, beating the analyst consensus loss estimate of 38 cents.

4 months ago - Benzinga

Exact Sciences to Participate in May Investor Conference

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the follow...

4 months ago - Business Wire

Exact Sciences Corporation (EXAS) Q1 2025 Earnings Call Transcript

Exact Sciences Corporation. (NASDAQ:EXAS) Q1 2025 Earnings Conference Call May 1, 2025 5:00 PM ET Company Participants Derek Leckow - Vice President, Investor Relations Kevin Conroy - Chairman and Ch...

4 months ago - Seeking Alpha

Exact Sciences Announces First-Quarter 2025 Results

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $707 million for...

4 months ago - Business Wire